Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.
暂无分享,去创建一个
Chris Bailey-Kellogg | Deeptak Verma | Karl E Griswold | Yoonjoo Choi | Christian Ndong | Wen Li | Hongliang Zhao | C. Bailey-Kellogg | S. Fiering | C. Ndong | K. Griswold | Deeptak Verma | Yoonjoo Choi | Steven N Fiering | Wen Li | Hongliang Zhao | C. NDong
[1] Chris Bailey-Kellogg,et al. Protein deimmunization via structure‐based design enables efficient epitope deletion at high mutational loads , 2015, Biotechnology and bioengineering.
[2] Regina S. Salvat,et al. Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance , 2015, Molecular therapy. Methods & clinical development.
[3] Chris Bailey-Kellogg,et al. Structure‐based design of combinatorial mutagenesis libraries , 2015, Protein science : a publication of the Protein Society.
[4] R. James,et al. Crystal structure of the antimicrobial peptidase lysostaphin from Staphylococcus simulans , 2014, The FEBS journal.
[5] David Baker,et al. Removing T-cell epitopes with computational protein design , 2014, Proceedings of the National Academy of Sciences.
[6] D. Baker,et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes , 2014, Proceedings of the National Academy of Sciences.
[7] Chris Bailey-Kellogg,et al. A high throughput MHC II binding assay for quantitative analysis of peptide epitopes. , 2014, Journal of visualized experiments : JoVE.
[8] Chris Bailey-Kellogg,et al. Gene and Protein Sequence Optimization for High-Level Production of Fully Active and Aglycosylated Lysostaphin in Pichia pastoris , 2014, Applied and Environmental Microbiology.
[9] K. Griswold,et al. A high‐throughput screen for antibiotic drug discovery , 2014, Biotechnology and bioengineering.
[10] Saurabh Aggarwal,et al. What's fueling the biotech engine—2012 to 2013 , 2014, Nature Biotechnology.
[11] Vibha Jawa,et al. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.
[12] Chris Bailey-Kellogg,et al. Structure‐based redesign of proteins for minimal T‐cell epitope content , 2013, J. Comput. Chem..
[13] Ronit Mazor,et al. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.
[14] J. Cizeau,et al. Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. , 2012, Cancer biotherapy & radiopharmaceuticals.
[15] R. Kotłowski,et al. Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus , 2012, Applied Microbiology and Biotechnology.
[16] Chris Bailey-Kellogg,et al. Design and analysis of immune-evading enzymes for ADEPT therapy. , 2012, Protein engineering, design & selection : PEDS.
[17] Dan S. Tawfik,et al. Directed enzyme evolution: beyond the low-hanging fruit. , 2012, Current opinion in structural biology.
[18] Chris Bailey-Kellogg,et al. Structure-Guided Deimmunization of Therapeutic Proteins , 2012, RECOMB.
[19] Chris Bailey-Kellogg,et al. A divide‐and‐conquer approach to determine the Pareto frontier for optimization of protein engineering experiments , 2012, Proteins.
[20] V. Fischetti,et al. PEGylating a bacteriophage endolysin inhibits its bactericidal activity , 2011, AMB Express.
[21] Chris Bailey-Kellogg,et al. Optimization of Therapeutic proteins to Delete T-Cell epitopes while Maintaining Beneficial Residue Interactions , 2011, J. Bioinform. Comput. Biol..
[22] F. Arnold,et al. Optimizing non-natural protein function with directed evolution. , 2011, Current opinion in chemical biology.
[23] George Georgiou,et al. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.
[24] Morten Nielsen,et al. Peptide binding predictions for HLA DR, DP and DQ molecules , 2010, BMC Bioinformatics.
[25] Yoonjoo Choi,et al. FREAD revisited: Accurate loop structure prediction using a database search algorithm , 2010, Proteins.
[26] R. Dubridge,et al. The immunogenicity of humanized and fully human antibodies , 2010, mAbs.
[27] Tim D. Jones,et al. Prediction of Immunogenicity of Therapeutic Proteins , 2010, BioDrugs.
[28] I. Pastan,et al. Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P , 2009, Clinical Cancer Research.
[29] J. Cizeau,et al. Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin , 2009, Journal of immunotherapy.
[30] Gevorg Grigoryan,et al. Design of protein-interaction specificity affords selective bZIP-binding peptides , 2009, Nature.
[31] Amy C. Anderson,et al. Computational structure-based redesign of enzyme activity , 2009, Proceedings of the National Academy of Sciences.
[32] F. Niesen,et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.
[33] Bruce Tidor,et al. Progress in computational protein design. , 2007, Current opinion in biotechnology.
[34] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[35] A. Sali,et al. Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.
[36] Fei Zhou,et al. Ultra-Fast Evaluation of Protein Energies Directly from Sequence , 2006, PLoS Comput. Biol..
[37] M. Sugai,et al. Cell Wall-targeting Domain of Glycylglycine Endopeptidase Distinguishes among Peptidoglycan Cross-bridges* , 2006, Journal of Biological Chemistry.
[38] M. Bochtler,et al. Crystal structures of active LytM. , 2005, Journal of molecular biology.
[39] Wolfgang Aehle,et al. A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.
[40] S. Larson,et al. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.
[41] S. G. Odintsov,et al. Latent LytM at 1.3A resolution. , 2004, Journal of molecular biology.
[42] S. Walsh,et al. Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol , 2003, Antimicrobial Agents and Chemotherapy.
[43] Huub Schellekens,et al. Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.
[44] Marc De Maeyer,et al. Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.
[45] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[46] T L Blundell,et al. Crystal structures of NK1–heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor , 2001, The EMBO journal.
[47] A. Sali,et al. Protein Structure Prediction and Structural Genomics , 2001, Science.
[48] J. Richardson,et al. The penultimate rotamer library , 2000, Proteins.
[49] Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.
[50] G. Jackowski,et al. Removal of endotoxin from recombinant protein preparations. , 1997, Clinical Biochemistry.
[51] F. Falcioni,et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis , 1996, The Journal of experimental medicine.
[52] Peter A. Kollman,et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .
[53] W. C. Still,et al. Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .
[54] M. Artenstein,et al. Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient. , 1974, The New England journal of medicine.
[55] P. Y. Chou,et al. Prediction of protein conformation. , 1974, Biochemistry.
[56] Pablo Gainza,et al. Osprey: Protein Design with Ensembles, Flexibility, and Provable Algorithms , 2022 .
[57] E. Mylonakis,et al. Lysostaphin: a silver bullet for staph. , 2012 .
[58] Narayanan Eswar,et al. Protein structure modeling with MODELLER. , 2008, Methods in molecular biology.
[59] Ira Mellman,et al. Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.
[60] E. Panosyan,et al. Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations , 2005, Clinical pharmacokinetics.
[61] David Baker,et al. Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.
[62] G. Letchworth,et al. High efficiency transformation by electroporation of Pichia pastoris pretreated with lithium acetate and dithiothreitol. , 2004, BioTechniques.
[64] J. Skolnick,et al. Scoring function for automated assessment of protein structure template quality , 2004, Proteins.